Mi a nyitvatartási idő?

Hétfő 08:30 - 17:00 Kedd 08:30 - 17:00 Szerda 08:30 - 17:00 Csütörtök 08:30 - 17:00 Péntek 08:30 - 17:00

Wlcus, kiraly Utca 26, Budapest (2026)

29/07/2026

🚨 𝗜𝘀 𝘆𝗼𝘂𝗿 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗘𝗨 𝗛𝗧𝗔 𝘀𝗰𝗿𝘂𝘁𝗶𝗻𝘆?

Regulatory approval is no longer the finish line.

Under the EU HTA Regulation, pharmaceutical and biotech companies must demonstrate that their evidence can withstand rigorous assessment from HTA bodies, payers, and decision-makers, not just regulators.

Leading organizations are now 𝘀𝘁𝗿𝗲𝘀𝘀-𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 by asking critical questions such as:

• Is our comparator aligned with real clinical practice?
• Does our evidence fully address the agreed PICO?
• Where can Real-World Evidence reduce uncertainty?
• Are we prepared for the toughest HTA questions before
submission?

The 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗴𝗮𝗽𝘀 𝗲𝗮𝗿𝗹𝘆 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗯𝗲𝘁𝘁𝗲𝗿 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗲𝗱 𝗳𝗼𝗿 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗮𝗻𝗱 𝗳𝗮𝘀𝘁𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗰𝗰𝗲𝘀𝘀.

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://wlcus.com/eu-hta-market-access-strategy-pharma/

🎯 𝗧𝗵𝗲𝘀𝗲 𝗮𝗿𝗲 𝗲𝘅𝗮𝗰𝘁𝗹𝘆 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝗽𝗹𝗮𝗰𝗲 at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲, taking place on 𝟮𝟭–𝟮𝟮 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟲 at 𝗜𝗻𝗻𝘁𝗲𝗹 𝗛𝗼𝘁𝗲𝗹𝘀 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸.

𝗦𝗲𝗻𝗶𝗼𝗿 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗣𝗵𝗮𝗿𝗺𝗮, 𝗕𝗶𝗼𝘁𝗲𝗰𝗵, 𝗛𝗧𝗔, 𝗛𝗘𝗢𝗥, 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 & 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 will explore how to build evidence strategies that succeed in the EU HTA era.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗮𝗴𝗲𝗻𝗱𝗮 𝗼𝗿 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝘁𝗼𝗱𝗮𝘆: https://wlcus.com/event/rwe_market_access_event_2026/

𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 at www.wlcus.com
𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 at 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺 or 𝗰𝗮𝗹𝗹 𝘂𝘀 at +𝟯𝟲𝟯𝟬𝟴𝟮𝟴𝟮𝟮𝟯𝟵

22/07/2026

🚀 𝗛𝗼𝘄 𝗦𝗪𝗜𝗙𝗧'𝘀 𝗡𝗲𝘄 𝗖𝗿𝗼𝘀𝘀-𝗕𝗼𝗿𝗱𝗲𝗿 𝗣𝗮𝘆𝗺𝗲𝗻𝘁 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗜𝘀 𝗥𝗲𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗣𝗮𝘆𝗺𝗲𝗻𝘁𝘀

𝗖𝗿𝗼𝘀𝘀-𝗯𝗼𝗿𝗱𝗲𝗿 𝗽𝗮𝘆𝗺𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝗲𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝗮 𝗻𝗲𝘄 𝗲𝗿𝗮.

As customer expectations rise and global commerce accelerates, financial institutions are under increasing pressure to deliver faster settlement, greater transparency, stronger interoperability, and more intelligent payment experiences.

SWIFT's latest cross-border payment framework represents another important step toward modernizing international payments, helping banks, payment providers, fintechs, and corporates navigate the next generation of global financial infrastructure.

𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝘀:
• Faster cross-border settlement
• Enhanced payment transparency
• Interoperability across modern payment ecosystems
• AI-powered payment orchestration
• ISO 20022 and payment modernization
• The future of stablecoins, tokenized assets, and CBDCs

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: 𝗖𝗹𝗶𝗰𝗸 𝗛𝗲𝗿𝗲: https://wlcus.com/swift-cross-border-payment-framework/

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗔𝗴𝗲𝗻𝗱𝗮: 𝗖𝗹𝗶𝗰𝗸 𝗛𝗲𝗿𝗲: https://wlcus.com/event/next-gen-payments-summit-europe/

𝗝𝗼𝗶𝗻 𝘂𝘀 at 𝗧𝗵𝗲 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻 𝗣𝗮𝘆𝗺𝗲𝗻𝘁𝘀 𝗕𝗹𝘂𝗲𝗽𝗿𝗶𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟳, where senior leaders from banks, payment service providers, fintechs, regulators, merchants, and technology innovators will explore the future of payments, digital finance, and financial infrastructure.

𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱 𝗶𝗻 𝘀𝗽𝗲𝗮𝗸𝗶𝗻𝗴 𝗼𝗿 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝘀𝗽𝗼𝗻𝘀𝗼𝗿?

𝗘𝗺𝗮𝗶𝗹: 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺
📞 𝗖𝗮𝗹𝗹: +𝟯𝟲 𝟯𝟬 𝟴𝟮𝟴 𝟮𝟮𝟯𝟵

22/07/2026

𝗙𝗔𝗖𝗧: 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (𝗥𝗪𝗘) 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝗷𝘂𝘀𝘁 𝗮 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝘁𝗼𝗼𝗹, 𝗶𝘁'𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝗰𝗼𝗿𝗲 𝗽𝗶𝗹𝗹𝗮𝗿 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲'𝘀 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲.

The European Medicines Agency's DARWIN EU® initiative continues to strengthen the use of Real-World Evidence in regulatory decision-making across Europe.

𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝘁𝗼 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝘂𝗽𝗱𝗮𝘁𝗲:
🔹 40 data partners across 18 European countries
🔹 Access to healthcare data representing approximately 250
million patients
🔹 A 49% increase in regulator-led Real-World Evidence studies
compared with the previous reporting period

These developments signal a broader shift towards integrating high-quality real-world data into regulatory assessments, pharmacovigilance, and evidence generation.

𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿?
For Market Access, HEOR, Medical Affairs, and Regulatory teams, evidence generation is no longer something that begins after approval. It is becoming an integral part of product strategy from the earliest stages of development.

As regulatory expectations continue to evolve under the EU HTA framework, organisations that invest in robust Real-World Evidence capabilities and cross-functional collaboration will be better positioned for successful regulatory and reimbursement outcomes.

𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀?

Do you believe Real-World Evidence will become as influential as traditional clinical trial data in future regulatory and HTA decision-making across Europe?

22/07/2026

🚨 𝗘𝗨 𝗛𝗧𝗔 𝗶𝘀 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝘂𝗹𝗲𝘀 𝗼𝗳 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀. 𝗜𝘀 𝘆𝗼𝘂𝗿 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗸𝗲𝗲𝗽𝗶𝗻𝗴 𝘂𝗽?

The 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗺𝗼𝗿𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗶𝘁'𝘀 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗮𝘁 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗶𝗺𝗲, 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗰𝗿𝗼𝘀𝘀-𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻.

As 𝗘𝗨 𝗛𝗧𝗔, 𝗝𝗼𝗶𝗻𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁𝘀 (𝗝𝗖𝗔), 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (𝗥𝗪𝗘), 𝗮𝗻𝗱 𝗔𝗜 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝘁𝗼 𝗿𝗲𝘀𝗵𝗮𝗽𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻, 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 (𝗜𝗘𝗣) is 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗽𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝗳𝘂𝘁𝘂𝗿𝗲 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀.

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://wlcus.com/integrated-evidence-planning-eu-hta/

𝗪𝗮𝗻𝘁 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲𝘀𝗲 𝘁𝗼𝗽𝗶𝗰𝘀 𝘄𝗶𝘁𝗵 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗹𝗲𝗮𝗱𝗲𝗿𝘀?

𝗝𝗼𝗶𝗻 𝘂𝘀 at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲 (𝟮𝟭–𝟮𝟮 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟲, 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺), where senior experts will discuss:

• Integrated Evidence Planning
• EU HTA & Joint Clinical Assessments
• PICO Strategy
• Real-World Evidence
• AI in Evidence Generation
• Pricing & Market Access

𝗖𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 to 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗔𝗴𝗲𝗻𝗱𝗮: https://wlcus.com/event/rwe_market_access_event_2026/
𝗖𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 to 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗛𝗲𝗿𝗲: https://wlcus.com/event/rwe_market_access_event_2026/

For 𝗚𝗿𝗼𝘂𝗽 𝗱𝗲𝗹𝗲𝗴𝗮𝘁𝗲 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻𝘀, 𝘀𝗽𝗼𝗻𝘀𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀, 𝗼𝗿 𝗮𝗻𝘆 𝗲𝗻𝗾𝘂𝗶𝗿𝗶𝗲𝘀:

📧 [email protected]
📞 +36 30 828 2239

22/07/2026

🎙️ 𝗦𝗣𝗘𝗔𝗞𝗘𝗥 𝗔𝗡𝗡𝗢𝗨𝗡𝗖𝗘𝗠𝗘𝗡𝗧 & 𝗚𝗢𝗟𝗗 𝗣𝗔𝗥𝗧𝗡𝗘𝗥

As the implementation of the regulation reshapes European market entry, waiting until Phase III to align regulatory, HTA, and market access strategies is no longer a viable option. Early alignment on clinical evidence requirements is now the single biggest factor in avoiding launch delays and securing reimbursement across EU member states.

𝗪𝗲 𝗮𝗿𝗲 𝘁𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 DLRC Regulatory Consultancy 𝗮𝘀 𝗼𝘂𝗿 𝗚𝗼𝗹𝗱 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 𝗮𝗻𝗱 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 Carolin Knorr-Hendreich, 𝗛𝗧𝗔 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗣𝗿𝗶𝗻𝗰𝗶𝗽𝗮𝗹 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁, 𝗮𝘀 𝗮 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗼𝗻 𝗗𝗮𝘆 𝟭 𝗼𝗳 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲 ( #𝗝𝗖𝗔 & #𝗣𝗜𝗖𝗢 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗘𝗱𝗶𝘁𝗶𝗼𝗻)!

🎙️𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝘁𝗮𝗶𝗹𝘀:

📌 𝗧𝗼𝗽𝗶𝗰: "𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝘄𝗮𝗿𝗱𝘀 𝗘𝗮𝗿𝗹𝘆 𝗔𝗹𝗶𝗴𝗻𝗺𝗲𝗻𝘁 𝗼𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗛𝗧𝗔 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲"

💡 𝗪𝗵𝘆 𝗬𝗼𝘂 𝗖𝗮𝗻'𝘁 𝗠𝗶𝘀𝘀 𝗧𝗵𝗶𝘀 𝗦𝗲𝘀𝘀𝗶𝗼𝗻:
Carolin will unpack how cross-functional teams in , and can break down silos early in development to build cohesive evidence packages that satisfy both regulatory bodies (EMA) and national HTA authorities.

𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:
• 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗛𝗧𝗔, 𝗮𝗻𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀
𝗴𝗼𝗮𝗹𝘀 𝗲𝗮𝗿𝗹𝘆 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁.
• 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗺𝘂𝗹𝘁𝗶-𝗰𝗼𝘂𝗻𝘁𝗿𝘆 #𝗣𝗜𝗖𝗢 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗲𝘅𝗽𝗲𝗰𝘁𝗮𝘁𝗶𝗼𝗻𝘀
𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗰𝗼𝗺𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗹𝗮𝘂𝗻𝗰𝗵 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲𝘀.
• 𝗔𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸𝘀 𝗳𝗼𝗿 𝗰𝗿𝗼𝘀𝘀-𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗹𝗶𝗴𝗻𝗺𝗲𝗻𝘁 𝘂𝗻𝗱𝗲𝗿
𝘁𝗵𝗲 𝗮𝗰𝘁𝗶𝘃𝗲

#𝗝𝗼𝗶𝗻𝘁𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 (𝗝𝗖𝗔).

𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁
📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟭 - 𝟮𝟮, 𝟮𝟬𝟮𝟲 | 𝗜𝗻𝗻𝘁𝗲𝗹 𝗛𝗼𝘁𝗲𝗹𝘀 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸
𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗔𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲: https://lnkd.in/dvNcM9_P

👉 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆! 𝗦𝗰𝗮𝗻 𝘁𝗵𝗲 𝗤𝗥 𝗰𝗼𝗱𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗮𝗻𝗻𝗲𝗿 𝗼𝗿

𝗙𝗼𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘃𝗶𝘀𝗶𝘁: https://lnkd.in/dsFA8rAY
or 𝗖𝗮𝗹𝗹 𝘂𝘀: +36 30 828 2239

For 𝗴𝗿𝗼𝘂𝗽 𝗯𝗼𝗼𝗸𝗶𝗻𝗴𝘀 or 𝘁𝗼 𝗿𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝗮𝗴𝗲𝗻𝗱𝗮, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 at 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺.

📧 Contact: [email protected] | 📞 +36 30 8282239

15/07/2026

🎤 𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁:

To satisfy evolving joint health technology assessments, pharmaceutical access and evidence teams must scale their 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 ( #𝗥𝗪𝗘) 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻, without compromising on absolute patient privacy or data sovereignty.

𝗪𝗲 𝗮𝗿𝗲 𝘁𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 Hélène Karcher, PhD, 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗟𝗲𝗮𝗱𝗲𝗿 𝗮𝘁 Roche, 𝘁𝗼 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺!

𝗛𝗲𝗹𝗲𝗻𝗲 will be delivering a highly anticipated, specialized session on:

"𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗥𝗪𝗘 & 𝗔𝗜: 𝗙𝗲𝗱𝗲𝗿𝗮𝘁𝗲𝗱 𝗗𝗮𝘁𝗮 𝗮𝗻𝗱 𝗣𝗿𝗶𝘃𝗮𝗰𝘆-𝗣𝗿𝗲𝘀𝗲𝗿𝘃𝗶𝗻𝗴 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀"

As European evidence demands intensify under the new JCA frameworks, this session will dive straight into:

• 𝗙𝗲𝗱𝗲𝗿𝗮𝘁𝗲𝗱 𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴
• 𝗣𝗿𝗶𝘃𝗮𝗰𝘆 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀
• 𝗔𝗜 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻

Don't miss this opportunity to master the future of secure, decentralized data.

𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁
📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟭 - 𝟮𝟮, 𝟮𝟬𝟮𝟲 | 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺, 𝗧𝗵𝗲 𝗡𝗲𝘁𝗵𝗲𝗿𝗹𝗮𝗻𝗱𝘀
𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗔𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲: https://wlcus.com/event/rwe_market_access_event_2026/
𝗙𝗼𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘃𝗶𝘀𝗶𝘁: https://wlcus.com/event/rwe_market_access_event_2026/

👉 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆! 𝗦𝗰𝗮𝗻 𝘁𝗵𝗲 𝗤𝗥 𝗰𝗼𝗱𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗮𝗻𝗻𝗲𝗿 𝗼𝗿

or 𝗖𝗮𝗹𝗹 𝘂𝘀: +36 30 828 2239

For 𝗴𝗿𝗼𝘂𝗽 𝗯𝗼𝗼𝗸𝗶𝗻𝗴𝘀 or 𝘁𝗼 𝗿𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝗮𝗴𝗲𝗻𝗱𝗮, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 at 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺.

14/07/2026

🎤 "𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁"

As we prepare for the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲 in Amsterdam, the legal and regulatory realities underpinning long-term access strategies have never been more critical.

𝗪𝗲 𝗮𝗿𝗲 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝘆 𝗵𝗼𝗻𝗼𝗿𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘁𝗵𝗮𝘁 Stefano Marino, 𝗳𝗼𝗿𝗺𝗲𝗿 𝗛𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗟𝗲𝗴𝗮𝗹 𝗗𝗲𝗽𝗮𝗿𝘁𝗺𝗲𝗻𝘁 𝗮𝘁 𝘁𝗵𝗲 European Medicines Agency (𝗘𝗠𝗔) 𝗮𝗻𝗱 𝗰𝘂𝗿𝗿𝗲𝗻𝘁𝗹𝘆 𝗦𝗲𝗻𝗶𝗼𝗿 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁 𝗮𝘁 DLA Piper, 𝗶𝘀 𝗷𝗼𝗶𝗻𝗶𝗻𝗴 𝗼𝘂𝗿 𝗲𝘅𝗽𝗲𝗿𝘁 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗳𝗮𝗰𝘂𝗹𝘁𝘆!

During his decade-long tenure leading the EMA’s legal operations, Stefano was at the absolute forefront of defining EU pharmaceutical policy. He spearheaded critical frameworks, including:

• 𝗣𝗼𝗹𝗶𝗰𝘆 𝟬𝟬𝟳𝟬 𝗼𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗿𝗲𝗽𝗼𝗿𝘁 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀
• 𝗧𝗵𝗲 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻
• 𝗛𝗶𝗴𝗵-𝗹𝗲𝘃𝗲𝗹 𝗮𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗽𝗮𝘁𝗵𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗱𝗿𝗮𝗳𝘁 𝗘𝗨 𝗣𝗵𝗮𝗿𝗺𝗮
𝗟𝗮𝘄 𝗥𝗲𝗳𝗼𝗿𝗺

At the summit, 𝗦𝘁𝗲𝗳𝗮𝗻𝗼 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗯𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝘂𝗻𝗽𝗮𝗿𝗮𝗹𝗹𝗲𝗹𝗲𝗱 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝘁𝗵 𝘁𝗼 𝗼𝘂𝗿 𝗵𝗶𝗴𝗵𝗹𝘆 𝗮𝗻𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲𝗱 𝗰𝗹𝗼𝘀𝗶𝗻𝗴 𝘀𝗲𝘀𝘀𝗶𝗼𝗻:

𝗖𝗹𝗼𝘀𝗶𝗻𝗴 𝗣𝗮𝗻𝗲𝗹: 𝗔𝗰𝗰𝗲𝘀𝘀 𝟮𝟬𝟯𝟬 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀

• 𝗙𝘂𝘁𝘂𝗿𝗲 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗼𝗳 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲-
𝗯𝗮𝘀𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴.
• 𝗟𝗼𝗻𝗴-𝗧𝗲𝗿𝗺 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹
𝗮𝗰𝗰𝗲𝘀𝘀 𝗮𝗻𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝘁𝗲𝗮𝗺𝘀 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴
𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗯𝗮𝘀𝗲𝗹𝗶𝗻𝗲𝘀.

Join Stefano and other global access leaders this October to secure your team’s strategic readiness.

𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁

📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟭 - 𝟮𝟮, 𝟮𝟬𝟮𝟲 | 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺, 𝗧𝗵𝗲 𝗡𝗲𝘁𝗵𝗲𝗿𝗹𝗮𝗻𝗱𝘀
𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗔𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲: https://wlcus.com/event/rwe_market_access_event_2026/

👉 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆! 𝗦𝗰𝗮𝗻 𝘁𝗵𝗲 𝗤𝗥 𝗰𝗼𝗱𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗮𝗻𝗻𝗲𝗿 𝗼𝗿

𝗙𝗼𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘃𝗶𝘀𝗶𝘁: https://wlcus.com/event/rwe_market_access_event_2026/ 𝗖𝗮𝗹𝗹 𝘂𝘀: +36 30 828 2239

For 𝗴𝗿𝗼𝘂𝗽 𝗯𝗼𝗼𝗸𝗶𝗻𝗴𝘀 or 𝘁𝗼 𝗿𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝗮𝗴𝗲𝗻𝗱𝗮, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 at 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺.

13/07/2026

💶 Is 𝗘𝘂𝗿𝗼𝗽𝗲 𝗔𝗯𝗼𝘂𝘁 𝘁𝗼 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗲 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗣𝗮𝘆𝗺𝗲𝗻𝘁𝘀?

The 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗘𝘂𝗿𝗼 is no longer just a concept, it has become one of the most important strategic initiatives shaping Europe's financial future.

Designed by the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗕𝗮𝗻𝗸 (𝗘𝗖𝗕), the Digital Euro aims to strengthen payment sovereignty, support innovation, improve financial resilience, and provide a secure public digital payment option across the Eurozone.

For banks, payment providers, fintechs, merchants, and financial institutions, this isn't simply another payment method, it could fundamentally reshape how digital payments operate across Europe.

📌 In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗿𝘁𝗶𝗰𝗹𝗲, 𝘄𝗲 𝗲𝘅𝗽𝗹𝗼𝗿𝗲:

• What the Digital Euro is and how it differs from cryptocurrencies
• Why Europe is investing in a Central Bank Digital Currency
(CBDC)
• The five strategic objectives behind the Digital Euro
• What it means for banks, payment service providers, and fintechs
• Key opportunities and implementation challenges
• How it could influence PSD3, Open Finance, Instant Payments,

Digital Identity, and the future of European payments

As 𝗘𝘂𝗿𝗼𝗽𝗲 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝘀 𝗺𝗼𝗱𝗲𝗿𝗻𝗶𝘀𝗶𝗻𝗴 𝗶𝘁𝘀 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗘𝘂𝗿𝗼 𝗶𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆 𝗽𝗮𝘆𝗺𝗲𝗻𝘁𝘀 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹.

📖 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://wlcus.com/digital-euro-future-of-european-payments/

The 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗘𝘂𝗿𝗼 𝗮𝗻𝗱 𝗺𝗮𝗻𝘆 𝗼𝘁𝗵𝗲𝗿 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝘁𝗿𝗲𝗻𝗱𝘀 𝘄𝗶𝗹𝗹 𝗮𝗹𝘀𝗼 𝗯𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗲𝗱 at 𝗧𝗵𝗲 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻 𝗣𝗮𝘆𝗺𝗲𝗻𝘁𝘀 𝗕𝗹𝘂𝗲𝗽𝗿𝗶𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟳, where industry leaders will explore the future of payments, financial infrastructure, regulation, AI, and digital finance.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗔𝗴𝗲𝗻𝗱𝗮: https://wlcus.com/event/next-gen-payments-summit-europe/

💬 𝗗𝗼 𝘆𝗼𝘂 𝗯𝗲𝗹𝗶𝗲𝘃𝗲 𝘁𝗵𝗲 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗘𝘂𝗿𝗼 𝘄𝗶𝗹𝗹 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲'𝘀 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺, 𝗼𝗿 𝗰𝗿𝗲𝗮𝘁𝗲 𝗻𝗲𝘄 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗳𝗼𝗿 𝗯𝗮𝗻𝗸𝘀 𝗮𝗻𝗱 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿𝘀?

𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗯𝘆 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝗶𝗻𝗴 𝗯𝗲𝗹𝗼𝘄.

13/07/2026

🚨 𝗧𝗵𝗲 𝗙𝗶𝗿𝘀𝘁 𝗧𝗵𝗿𝗲𝗲 𝗘𝗨 𝗝𝗼𝗶𝗻𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 (𝗝𝗖𝗔) 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗔𝗿𝗲 𝗛𝗲𝗿𝗲

The first three official 𝗘𝗨 𝗝𝗼𝗶𝗻𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 (𝗝𝗖𝗔) 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 are now setting the benchmark for how clinical evidence will be evaluated under the new 𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 (𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 (𝗘𝗨) 𝟮𝟬𝟮𝟭/𝟮𝟮𝟴𝟮).

These landmark assessments could shape the future of 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀, 𝗛𝗘𝗢𝗥, 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (𝗥𝗪𝗘), 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀, 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 & 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲.

If your organisation is preparing for future EU HTA submissions, these reports provide valuable insights into the evolving evidence landscape.

📖 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗸𝗲𝘆 𝗹𝗲𝘀𝘀𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗵𝗿𝗲𝗲 𝗝𝗖𝗔 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗲𝘆 𝗰𝗼𝘂𝗹𝗱 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗳𝘂𝘁𝘂𝗿𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://wlcus.com/first-four-eu-joint-clinical-assessment-jca-reports/

𝗝𝗼𝗶𝗻 𝘂𝘀 at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲, where 𝘀𝗲𝗻𝗶𝗼𝗿 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀, 𝗛𝗧𝗔 𝗯𝗼𝗱𝗶𝗲𝘀, 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝗹𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝘁𝗵𝗲 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, 𝗣𝗜𝗖𝗢 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆, 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗔𝗜 𝗶𝗻 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗔𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲: https://wlcus.com/event/rwe_market_access_event_2026/

💬 𝗪𝗵𝗮𝘁 𝗱𝗼 𝘆𝗼𝘂 𝘁𝗵𝗶𝗻𝗸 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝘂𝗻𝗱𝗲𝗿 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗘𝗨 𝗛𝗧𝗔 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸?

13/07/2026

🎤𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁:

𝗧𝗵𝗲 𝗥𝗲𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗝𝗖𝗔 & 𝗣𝗜𝗖𝗢 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: 𝗠𝗼𝘃𝗶𝗻𝗴 𝗕𝗲𝘆𝗼𝗻𝗱 𝗧𝗵𝗲𝗼𝗿𝘆 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺

With the 𝗘𝗨 𝗝𝗼𝗶𝗻𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 (𝗝𝗖𝗔) fundamentally restructuring 𝗿𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁, the timeline for demonstrating absolute therapeutic value has compressed. For global asset owners, securing market access now hinges on operational decisions made years before launch.

𝗧𝗼 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝘁𝗵𝗲𝘀𝗲 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝘀𝗵𝗶𝗳𝘁𝘀, 𝘄𝗲 𝗮𝗿𝗲 𝗽𝗹𝗲𝗮𝘀𝗲𝗱 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 𝗩𝗶𝗰𝘁𝗼𝗿𝗶𝗮 𝗨𝗻𝗺𝘂𝗲𝘀𝘀𝗶𝗴, 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 - 𝗘𝗨 𝗛𝗧𝗔 𝗟𝗲𝗮𝗱 𝗮𝘁 𝗔𝗦𝗧𝗘𝗟𝗟𝗔𝗦 𝗣𝗵𝗮𝗿𝗺𝗮, 𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝗰𝘂𝗹𝘁𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲.

𝗩𝗶𝗰𝘁𝗼𝗿𝗶𝗮 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘀𝗽𝗲𝗮𝗿𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝗮𝗻𝗱 𝗺𝗼𝗱𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗲𝗻𝘁𝗶𝗿𝗲𝗹𝘆 𝗮𝗿𝗼𝘂𝗻𝗱 𝗰𝗿𝗼𝘀𝘀-𝗯𝗼𝗿𝗱𝗲𝗿 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹𝗶𝘁𝗶𝗲𝘀:

𝗣𝗮𝗻𝗲𝗹 𝗙𝗼𝗰𝘂𝘀: 𝗚𝗹𝗼𝗯𝗮𝗹 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗦𝗵𝗶𝗳𝘁𝘀, 𝗘𝗨 𝗛𝗧𝗔 & 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: 𝗪𝗵𝗮𝘁 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗡𝗲𝗲𝗱 𝘁𝗼 𝗣𝗿𝗲𝗽𝗮𝗿𝗲 𝗙𝗼𝗿

This panel bypasses standard regulatory summaries to dissect the friction points currently facing biopharma pipelines:

• 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗖𝗼𝗺𝗽𝗮𝗿𝗮𝘁𝗼𝗿 𝗥𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗲
• 𝗤𝘂𝗮𝗻𝘁𝗶𝗳𝘆𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁-𝗖𝗲𝗻𝘁𝗿𝗶𝗰 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲
• 𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗟𝗼𝗰𝗮𝗹 𝗗𝗶𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲

The Amsterdam forum is designed strictly for peer-to-peer benchmarking, bringing together senior directors to stress-test their launch strategies under the new regulatory pressures.

𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗥𝗪𝗘 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁

📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟭 - 𝟮𝟮, 𝟮𝟬𝟮𝟲 | 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺, 𝗧𝗵𝗲 𝗡𝗲𝘁𝗵𝗲𝗿𝗹𝗮𝗻𝗱𝘀

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗔𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲: https://wlcus.com/event/rwe_market_access_event_2026/

👉 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀 𝘁𝗼𝗱𝗮𝘆! 𝗦𝗰𝗮𝗻 𝘁𝗵𝗲 𝗤𝗥 𝗰𝗼𝗱𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗯𝗮𝗻𝗻𝗲𝗿 𝗼𝗿

𝗙𝗼𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘃𝗶𝘀𝗶𝘁: https://wlcus.com/event/rwe_market_access_event_2026/

or 𝗖𝗮𝗹𝗹 𝘂𝘀: +36 30 828 2239

For 𝗴𝗿𝗼𝘂𝗽 𝗯𝗼𝗼𝗸𝗶𝗻𝗴𝘀 or 𝘁𝗼 𝗿𝗲𝗾𝘂𝗲𝘀𝘁 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝗮𝗴𝗲𝗻𝗱𝗮, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 at 𝗯𝗼𝗼𝗸𝗶𝗻𝗴@𝘄𝗹𝗰𝘂𝘀.𝗰𝗼𝗺.

Wlcus

29/07/2026

22/07/2026

22/07/2026

22/07/2026

22/07/2026

15/07/2026

14/07/2026

13/07/2026

13/07/2026

13/07/2026

Cím

Nyitvatartási idő

Telefonszám

Weboldal

Értesítések

Parancsikonok

Megosztás

Kategória

Adatlap eltávolítási kérelme

Hétfő	08:30 - 17:00
Kedd	08:30 - 17:00
Szerda	08:30 - 17:00
Csütörtök	08:30 - 17:00
Péntek	08:30 - 17:00